Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (220)	5/14/2002 11:29:20 PM
From: scaram(o)uche	Read Replies (2) of 631

>> My comments were totally directed toward ABGX...as being bad for them. << I don't think that it's bad news for ABGX, much less the competitors (BTRN et al.). ABGX has come back 87% from the post-bubble high (11/00), and even more from the bubble high. It's selling at approximately 1.6X book, cash rich. Of the antibody companies, the quality and breadth of projects isn't touched -- IMO -- by the competition. A company doesn't rack up that sort of performance if there is not marked concern re. wasted burn, and anyone who reads this thread will realize that I was lamenting/criticizing the wasted burn. Whether or not it's popular opinion, it's my opinion that anti-IL-8 failure, or worse (continued, wasted burn), is priced in. We won't know tomorrow, while spin doctors are at work. Given ASCO, we may never have a good view. If ASCO is ABGX-neutral, we'll know in the middle of summer. We can agree to disagree. But, if there is further discussion, let's take it to T/FIF. Congrats re. your daughter's graduation.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next